London Genetics, Astrimmune to Seek PGx Markers for Investigational Pancreatic Cancer Vaccine | GenomeWeb

After observing differential response rates in clinical studies involving gastrin-blocking treatments, Astrimmune has decided to work with London Genetics to identify pharmacogenomic response markers to personalize a pancreatic cancer vaccine.

A grant from the UK's East Midlands Development Agency will support the biomarker discovery collaboration between London Genetics and Astrimmune, announced this week. The amount of the grant was not announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.